BioCentury | Aug 5, 2020
Management Tracks

CureVac makes Haas’ CEO job permanent; plus Zhang now CEO of Legend and updates from Royalty, NBE, Black Diamond, VelosBio and more

...same position at Ra Pharmaceuticals Inc., which UCB S.A. acquired for $2.3 billion last year. Sierra Oncology Inc....
...Pharma plc NBE-Therapeutics AG Black Diamond Therapeutics Inc. VelosBio Inc. Aspen Neuroscience Inc. Humanigen Inc. Engrail Therapeutics Inc. MiMedx Group Inc. Rhythm Pharmaceuticals Inc. Sierra Oncology Inc. Legend...
BioCentury | May 29, 2020
Management Tracks

Delaney takes over as Assembly’s CSO; plus NGM, TCR2, Amunix, Evox, Vor and more

...at Biogen Inc. (NASDAQ:BIIB). Effective June 1, Stephen Dilly will become president and CEO of Sierra Oncology Inc....
...Sawka, Staff Writer Assembly Biosciences Inc. NGM Biopharmaceuticals Inc. TCR2 Therapeutics Inc. Evox Therapeutics Ltd. Vor Biopharma Inc. BrainStorm Cell Therapeutics Inc. Sierra Oncology Inc. Science...
BioCentury | Mar 5, 2020
Finance

Amunix’s Omega-led $73M A round to support shift to drug development

...push into therapeutics; she was chief business and strategy officer and head of commercial at Sierra Oncology Inc....
BioCentury | Oct 30, 2019
Company News

Management tracks: Vectura, Editas, Assembly, Camp4, Tempus, Passage Bio, Boundless Bio and Prometheus

...company Boundless Bio Inc. hired Christian Hassig as CSO. He held the same position at Sierra Oncology Inc....
BioCentury | Jun 7, 2019
Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

...preclinical-stage synthetic lethality company founded by Versant Ventures in 2016. Presentations on compounds from KGaA, Sierra Oncology Inc....
...cancer. Atrin Pharmaceuticals LLC ’s ATRN-119 and ATRN-212 are in preclinical testing. 2. Chk1 inhibitors. Sierra Oncology Inc....
...Lilly and Co. (NYSE:LLY), Indianapolis, Ind. KGaA (Xetra:MRK), Darmstadt, Germany Repare Therapeutics Inc., St-Laurent, Quebec Sierra Oncology Inc....
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

...PSA declined ≥50% in 1 patient; stopped trial to reformulate to allow higher dosing e16517 Sierra Oncology Inc....
BioCentury | Jan 5, 2019
Company News

Flurry of management moves on eve of JPM

...CEO and appointed Rich Heyman as chairman. You was chief business and strategy officer at Sierra Oncology Inc....
BioCentury | Aug 31, 2018
Company News

Sierra Oncology acquires momelotinib from Gilead

...Inc. (NASDAQ:GILD), Foster City, Calif. Sierra Oncology Inc. (NASDAQ:SRRA), Vancouver, B.C. Business: Hematology Jaime De Leon momelotinib (cyt387) Gilead Sciences Inc. Sierra Oncology Inc. Janus...
BioCentury | Jun 9, 2018
Finance

ASCO ascent

...Aslan Pharmaceuticals Ltd. (NASDAQ:ASLN; TPEx:6497) $9.60 13% Hutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) $31.33 13% Sierra Oncology Inc....
BioCentury | Apr 7, 2017
Finance

Taking notice

...2/10/17 $20.1 $299.3 $382.4 28% Moleculin Biotech Inc. (NASDAQ:MBRX) (A) 2/9/17 $5.0 NA $20.1 NA Sierra Oncology Inc....
Items per page:
1 - 10 of 62
BioCentury | Aug 5, 2020
Management Tracks

CureVac makes Haas’ CEO job permanent; plus Zhang now CEO of Legend and updates from Royalty, NBE, Black Diamond, VelosBio and more

...same position at Ra Pharmaceuticals Inc., which UCB S.A. acquired for $2.3 billion last year. Sierra Oncology Inc....
...Pharma plc NBE-Therapeutics AG Black Diamond Therapeutics Inc. VelosBio Inc. Aspen Neuroscience Inc. Humanigen Inc. Engrail Therapeutics Inc. MiMedx Group Inc. Rhythm Pharmaceuticals Inc. Sierra Oncology Inc. Legend...
BioCentury | May 29, 2020
Management Tracks

Delaney takes over as Assembly’s CSO; plus NGM, TCR2, Amunix, Evox, Vor and more

...at Biogen Inc. (NASDAQ:BIIB). Effective June 1, Stephen Dilly will become president and CEO of Sierra Oncology Inc....
...Sawka, Staff Writer Assembly Biosciences Inc. NGM Biopharmaceuticals Inc. TCR2 Therapeutics Inc. Evox Therapeutics Ltd. Vor Biopharma Inc. BrainStorm Cell Therapeutics Inc. Sierra Oncology Inc. Science...
BioCentury | Mar 5, 2020
Finance

Amunix’s Omega-led $73M A round to support shift to drug development

...push into therapeutics; she was chief business and strategy officer and head of commercial at Sierra Oncology Inc....
BioCentury | Oct 30, 2019
Company News

Management tracks: Vectura, Editas, Assembly, Camp4, Tempus, Passage Bio, Boundless Bio and Prometheus

...company Boundless Bio Inc. hired Christian Hassig as CSO. He held the same position at Sierra Oncology Inc....
BioCentury | Jun 7, 2019
Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

...preclinical-stage synthetic lethality company founded by Versant Ventures in 2016. Presentations on compounds from KGaA, Sierra Oncology Inc....
...cancer. Atrin Pharmaceuticals LLC ’s ATRN-119 and ATRN-212 are in preclinical testing. 2. Chk1 inhibitors. Sierra Oncology Inc....
...Lilly and Co. (NYSE:LLY), Indianapolis, Ind. KGaA (Xetra:MRK), Darmstadt, Germany Repare Therapeutics Inc., St-Laurent, Quebec Sierra Oncology Inc....
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

...PSA declined ≥50% in 1 patient; stopped trial to reformulate to allow higher dosing e16517 Sierra Oncology Inc....
BioCentury | Jan 5, 2019
Company News

Flurry of management moves on eve of JPM

...CEO and appointed Rich Heyman as chairman. You was chief business and strategy officer at Sierra Oncology Inc....
BioCentury | Aug 31, 2018
Company News

Sierra Oncology acquires momelotinib from Gilead

...Inc. (NASDAQ:GILD), Foster City, Calif. Sierra Oncology Inc. (NASDAQ:SRRA), Vancouver, B.C. Business: Hematology Jaime De Leon momelotinib (cyt387) Gilead Sciences Inc. Sierra Oncology Inc. Janus...
BioCentury | Jun 9, 2018
Finance

ASCO ascent

...Aslan Pharmaceuticals Ltd. (NASDAQ:ASLN; TPEx:6497) $9.60 13% Hutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) $31.33 13% Sierra Oncology Inc....
BioCentury | Apr 7, 2017
Finance

Taking notice

...2/10/17 $20.1 $299.3 $382.4 28% Moleculin Biotech Inc. (NASDAQ:MBRX) (A) 2/9/17 $5.0 NA $20.1 NA Sierra Oncology Inc....
Items per page:
1 - 10 of 62